MDS sells its Central Labs operations to Czura Thornton

MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Central Labs operations to Czura Thornton, a private investment group based in Jersey, Channel Islands.

Central Labs provides a comprehensive range of late-stage laboratory services to global clients, including standardized assays, cardiac services, integrated data management, international laboratory study co-ordination and site support from 600 employees at six sites in Europe, North America and Asia.

"The completion of this transaction supports the Company's strategy to focus on its MDS Nordion business," said Stephen P. DeFalco, President and Chief Executive Officer of MDS Inc. "MDS Nordion remains committed to innovation and operational excellence to further build its leadership positions in the provision of medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies."

 

MDS Inc. Strategic Repositioning

 

On September 2, 2009, MDS announced it had reached an agreement with Danaher Corporation to sell its MDS Analytical Technologies business. The Company also announced that it intends to sell its remaining MDS Pharma Services business, a leading provider of innovative drug discovery and early-stage development solutions for pharmaceutical and biotechnology companies. Upon completion of these transactions, the Company will be focused solely on its MDS Nordion business, which is a leading provider of medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies. Additional background materials pertaining to the new strategic direction for MDS Inc. can be found on MDS Inc.'s Website at https://www.nordion.com/.

There can be no assurance that MDS will complete a transaction involving MDS Pharma Services. If MDS determines that there is not an acceptable transaction, it intends to retain and invest in building the business.

 

 

Source:

MDS INC.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Danaher. (2022, July 11). MDS sells its Central Labs operations to Czura Thornton. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20091102/MDS-sells-its-Central-Labs-operations-to-Czura-Thornton.aspx.

  • MLA

    Danaher. "MDS sells its Central Labs operations to Czura Thornton". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20091102/MDS-sells-its-Central-Labs-operations-to-Czura-Thornton.aspx>.

  • Chicago

    Danaher. "MDS sells its Central Labs operations to Czura Thornton". News-Medical. https://www.news-medical.net/news/20091102/MDS-sells-its-Central-Labs-operations-to-Czura-Thornton.aspx. (accessed April 23, 2024).

  • Harvard

    Danaher. 2022. MDS sells its Central Labs operations to Czura Thornton. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20091102/MDS-sells-its-Central-Labs-operations-to-Czura-Thornton.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Danaher offers GBP 50 million pounds for Genetix Group acquisition